|
|
|
09.10.25 - 09:54
|
Madrid Hospitals Overwhelmed By Illegals As Spaniards Endure Longer Healthcare Waits (ZeroHedge)
|
|
|
Madrid Hospitals Overwhelmed By Illegals As Spaniards Endure Longer Healthcare Waits
Authored by Thomas Brooke via Remix News,
Spain's public healthcare system is treating a growing number of undocumented migrants and displaced foreigners, despite Spaniards enduring increasingly longer waiting times for appointments and operations.
Figures released by Madrid's Ministry of Health show that the Spanish capital alone has registered a 44 percent jump in patients without residency papers in the last year, while the Canary Islands have agreed to take in sick and wounded minors from Gaza at the request of the central government, despite its own residents having to wait an average of 122 days for surgery appointments.
According to data published by El Confidencial, the Madrid Health Service (Sermas) provided medical care to 190,000 people in an irregular situation over the past year, compared with 134,000 the year before. The figure represents an increase of 60,000 patients in 12 months, as the reg...
|
|
|
01.10.25 - 15:06
|
Predicta Biosciences Secures $23.4M to Scale its Novel Diagnostic and Analytics Platform for Blood Cancers and Autoimmune Diseases (Business Wire)
|
|
|
Brian McKernan joins as CEO to further advance Predicta's clinical impact, including its non-invasive diagnostic for Multiple MyelomaCAMBRIDGE, Mass.--(BUSINESS WIRE)--Predicta Biosciences, a precision oncology company developing novel diagnostic and therapeutic discovery solutions, today announced it has raised an oversubscribed $23.4 million Series A led by Engine Ventures. Additional participating investors include Illumina Ventures, Lightchain Capital, Mass General Brigham Ventures, ACS BrightEdge, Binney Street Capital of Dana-Farber Cancer Institute and Myeloma Solutions Fund. The capital will be used to expand Predicta's team and CLIA-approved lab infrastructure, and advance commercialization of the company's first test, GenoPredicta and further development of other non-invasive diagnostic solutions for blood cancers and autoimmune diseases. In addition to the successful raise, Predicta also announced the appointment of Brian McKernan as CEO.
“It's an honor to join Predicta and our strong tea...
|
|
|
|
|
|
|
|
|
|
|
|
|
25.08.25 - 14:03
|
ORYZON Receives European Medicines Agency Approval to Initiate a Phase Ib Study of Iadademstat in Sickle Cell Disease (GlobeNewswire EN)
|
|
|
MADRID and CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, Ticker: ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, today announced that the European Medicines Agency (EMA) has approved its Clinical Trial Application (CTA), the European equivalent to an IND, to initiate a Phase Ib trial of iadademstat in sickle cell disease (SCD). This will be the first clinical trial investigating iadademstat in a non-malignant hematological indication....
|
|
|
07.08.25 - 08:03
|
Almirall and Absci Expand AI Drug Creation Collaboration Adding a Second Dermatology Target (GlobeNewswire EN)
|
|
|
BARCELONA, Spain and VANCOUVER, Wash., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Almirall (BME: ALM), a global biopharmaceutical company focused on medical dermatology, and Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative AI, today announced the expansion of their ongoing AI Drug Discovery collaboration with Almirall's selection of a second target aimed at dermatological indications....
|
|
|
04.08.25 - 13:03
|
Corporate News: Biotest AG (EQS)
|
|
|
Die Biotest AG erhält ein Einberufungsverlangen von Grifols S.A. für eine außerordentliche Hauptversammlung...
|
|
|
|
|
|
|
|
|
|
|
25.07.25 - 07:15
|
Almirall H1 2025 Results (Business Wire)
|
|
|
Almirall Continues to Deliver on its Long-Term Growth Strategy with Net Sales Growth of 12.7% in H1 2025, Driven by a Strong European Dermatology Business and Increasing Biologics Sales
Solid growth trajectory maintained: H1 net sales increased by 12.7% to €560.5 million, with EBITDA reaching €121.8 million (+16.6% YoY), driven by the strong performance of the biologics portfolio and operational excellence.
Biologics as key growth drivers: Ebglyss® achieved net sales of €44.9 million (>4x YoY) across 14 European countries. Ilumetri® continued its steady growth with a 12.7% increase in sales YoY, totaling €113.3 million in H1.
Sustained strong performance in Europe: Almirall's broad product portfolio underpins its leadership in medical dermatology, led by continued growth of Wynzora® (€17.1 million, +32.6% YoY) and Klisyri® (€13.7 million, +25.7% YoY).
Full-year guidance 2025 and mid-term outlook confirmed: Double-digit net sales growth and EBITDA targets remain on track, supported by robu...
|
|
|
|
|
|
|
|
|
14.07.25 - 14:03
|
ORYZON Continues to Strengthen its Patent Portfolio for Vafidemstat (GlobeNewswire EN)
|
|
|
MADRID and CAMBRIDGE, Mass., July 14, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, today announced that it has received “Decision to grant” communications from the Canadian Intellectual Property Office and the Israel Patent Office for its patent applications CA3071804 and IL272092, titled “Methods of treating behavior alterations”, related to vafidemstat, Oryzon's LSD1 inhibitor in clinical development for the treatment of psychiatric disorders....
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
